CytomX Therapeutics (CTMX) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 5.8% versus a loss of 26.7%. Over five years, DRUG leads with a +40.0% price change compared with -51.9% for CTMX. CytomX Therapeutics is the larger company by market cap ($543.7 million vs $541.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | DRUG |
|---|---|---|
| Share price | $2.50 | $54.94 |
| Market cap | $543.66M | $541.93M |
| 1-day change | +1.01% | +5.65% |
| YTD return | -42.02% | -33.37% |
| 1-year return | -26.71% | -5.80% |
| 5-year return | -51.95% | +39.97% |
| EPS (TTM) | $-0.51 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $123.75 |
| 52-week low | $2.43 | $47.23 |
| Distance from 52-week high | -69.61% | -55.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +390.98% | +176.61% |
| Average volume | 3.38M | 159.01K |
| Shares outstanding | 217.90M | 9.86M |
| Employees | 69 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRUG has outperformed CTMX by 20.9 percentage points over the past year.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
CTMX vs DRUG FAQ
Which is bigger, CytomX Therapeutics or Bright Minds Biosciences?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $543.66M compared with $541.93M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, CTMX or DRUG?
DRUG returned -5.80% over the past 12 months, compared with -26.71% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.